Neoadjuvant giredestrant plus palbociclib (P) vs. anastrozole (A) plus P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+, HER2-eBC): Patient (pt)-reported outcomes (PROs) in the randomized, open-label, international phase II coopERA BC study

被引：0
|
作者：
Park, Yeon Hee
Quiroga, Vanesa
Fasching, Peter A.
Bardia, Aditya
Lopez-Valverde, Vanesa
Crnjevic, Tanja Badovinac
Steinseifer, Jutta
Devine, Jacob
Hurvitz, Sara A.
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] GEICAM Spanish Breast Canc Grp, Madrid, Spain
[3] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Comprehens Canc Ctr CCC Erlangen EMN, Erlangen, Germany
[4] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] Genentech Inc, South San Francisco, CA USA
[7] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
591
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.
    Fasching, Peter A.
    Bardia, Aditya
    Quiroga, Vanesa
    Park, Yeon Hee
    Blancas, Isabel
    Alonso, Jose Luis
    Vasilyev, Alexander
    Adamchuk, Hryhoriy
    Salgado, Marcelo Ramos Tejo
    Yardley, Denise A.
    Spera, Gonzalo
    Xue, Cloris
    Ferreira, Erika
    Crnjevic, Tanja Badovinac
    Perez-Moreno, Pablo Diego
    Lopez-Valverde, Vanesa
    Steinseifer, Jutta
    Fernando, Tharu M.
    Moore, Heather M.
    Hurvitz, Sara A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Phase II neoadjuvant study of GDC-9545+palbociclib (palbo) vs anastrozole (A) plus palbo in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC)
    Hurvitz, Sara A.
    Fasching, Peter A.
    Park, Yeon Hee
    Quiroga, Vanesa
    Crnjevic, Tanja Badovinac
    Fresco, Rodrigo
    Lopez-Valverde, Vanesa
    Steinseifer, Jutta
    Ye, Chenglin
    Bardia, Aditya
    CANCER RESEARCH, 2021, 81 (04)
  • [3] Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) plus palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study
    Hurvitz, S. A.
    Park, Y. H.
    Bardia, A.
    Quiroga, V.
    Lopez-Valverde, V.
    Steinseifer, J.
    Moore, H. M.
    Spera, G.
    Xue, C.
    Fasching, P. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1285 - S1286
  • [4] Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole plus palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: Primary analysis of the randomized, open-label, phase II coopERA breast cancer study
    Hurvitz, Sara A.
    Quiroga, Vanesa
    Park, Yeon Hee
    Bardia, Aditya
    Lopez-Valverde, Vanesa
    Steinseifer, Jutta
    Fernando, Tharu M.
    Spera, Gonzalo
    Xue, Cloris
    Fasching, Peter A.
    CANCER RESEARCH, 2022, 82 (04)
  • [5] Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study
    Hurvitz, Sara A.
    Bardia, Aditya
    Quiroga, Vanesa
    Park, Yeon Hee
    Blancas, Isabel
    Alonso-Romero, Jose Luis
    Vasiliev, Aleksandr
    Adamchuk, Hryhoriy
    Salgado, Marcelo
    Yardley, Denise A.
    Berzoy, Oleksandr
    Zamora-Aunon, Pilar
    Chan, David
    Spera, Gonzalo
    Xue, Cloris
    Ferreira, Erika
    Crnjevic, Tanja Badovinac
    Perez-Moreno, Pablo Diego
    Lopez-Valverde, Vanesa
    Steinseifer, Jutta
    Fernando, Tharu M.
    Moore, Heather M.
    LANCET ONCOLOGY, 2023, 24 (09): : 1029 - 1041
  • [6] lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician's choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2-eBC)
    Geyer, Charles
    Bardia, Aditya
    Harbeck, Nadia
    Rimawi, Mothaffar F.
    Hurvitz, Sara A.
    Martin, Miguel
    Loi, Sherene
    Saji, Shigehira
    Jung, Kyung Hae
    Werutsky, Gustavo
    Stroyakovskiy, Daniil
    Lopez-Valverde, Vanesa
    Davis, Michael
    Crnjevic, Tanja Badovinac
    Perez-Moreno, Pablo Diego
    Schmid, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Exploratory gene expression analysis of coopERA Breast Cancer (BC): a study evaluating neoadjuvant giredestrant versus anastrozole alone and in combination with palbociclib in ER-positive, HER2-negative untreated early BC
    Chibly, Alejandro M.
    Fernando, Tharu M.
    Metcalfe, Ciara
    Hafner, Marc
    Owusu-Manu, Gilbert
    Hurvitz, Sara
    Bardia, Aditya
    Fasching, Peter A.
    Park, Yeon H.
    Quiroga, Vanesa
    Steinseifer, Jutta
    Perez-Moreno, Pablo
    Moore, Heather M.
    CANCER RESEARCH, 2023, 83 (05)
  • [8] evERA Breast Cancer (BC): Phase III study of giredestrant plus everolimus vs exemestane plus everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2-LA/mBC)
    Mayer, Erica L.
    Tolaney, Sara M.
    Brufsky, Adam
    Gradishar, William John
    Jhaveri, Komal L.
    Martin, Miguel
    Moscetti, Luca
    Schneeweiss, Andreas
    Vidal, Gregory A.
    Cortazar, Patricia
    Feldman, Merilin
    Day, Bann-mo
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician's choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+/HER2-EBC)
    Bardia, Aditya
    Schmid, Peter
    Harbeck, Nadia
    Rimawi, Mothaffar F.
    Hurvitz, Sara A.
    Loi, Sherene
    Saji, Shigehira
    Jung, Kyung Hae
    Werutsky, Gustavo
    Stroyakovskii, Daniil
    Lopez-Valverde, Vanesa
    Tesarowski, David
    Ye, Chenglin
    Davis, Michael
    Crnjevic, Tanja Badovinac
    Perez-Moreno, Pablo Diego
    Geyer, Charles E., Jr.
    CANCER RESEARCH, 2022, 82 (04)
  • [10] Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)
    Shimoi, Tatsunori
    Shimomura, Akihiko
    Shien, Tadahiko
    Uemura, Yukari
    Kato, Hiroaki
    Kitada, Masahiro
    Toyama, Tatsuya
    Aihara, Tomohiko
    Mukai, Hirofumi
    OPEN ACCESS JOURNAL OF CLINICAL TRIALS, 2018, 10 : 13 - 18
12345